Jeffrey Rona - Ovid Therapeutics Principal Officer
| OVID Stock | USD 1.43 0.01 0.70% |
Insider
Jeffrey Rona is Principal Officer of Ovid Therapeutics
| Age | 58 |
| Address | 441 Ninth Avenue, New York, NY, United States, 10001 |
| Phone | 646 661 7661 |
| Web | https://www.ovidrx.com |
Jeffrey Rona Latest Insider Activity
Tracking and analyzing the buying and selling activities of Jeffrey Rona against Ovid Therapeutics stock is an integral part of due diligence when investing in Ovid Therapeutics. Jeffrey Rona insider activity provides valuable insight into whether Ovid Therapeutics is net buyers or sellers over its current business cycle. Note, Ovid Therapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Ovid Therapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Jeffrey Rona over six months ago Disposition of 02 shares by Jeffrey Rona of Ovid Therapeutics at 0.56 subject to Rule 16b-3 | ||
Jeffrey Rona over six months ago Acquisition by Jeffrey Rona of 43750 shares of Ovid Therapeutics subject to Rule 16b-3 | ||
Jeffrey Rona over six months ago Acquisition by Jeffrey Rona of 43750 shares of Ovid Therapeutics subject to Rule 16b-3 | ||
Jeffrey Rona over six months ago Disposition of 02 shares by Jeffrey Rona of Ovid Therapeutics at 0.56 subject to Rule 16b-3 |
Ovid Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.2933) % which means that it has lost $0.2933 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6006) %, meaning that it created substantial loss on money invested by shareholders. Ovid Therapeutics' management efficiency ratios could be used to measure how well Ovid Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of February 17, 2026, Return On Tangible Assets is expected to decline to -0.27. In addition to that, Return On Capital Employed is expected to decline to -0.92. At present, Ovid Therapeutics' Total Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Intangible Assets is expected to grow to about 211.2 K, whereas Net Tangible Assets are forecasted to decline to about 81.7 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Martin Lehr | Context Therapeutics | 42 | |
| Roy MD | Oramed Pharmaceuticals | N/A | |
| MPH MD | Connect Biopharma Holdings | 54 | |
| CPA CPA | Clene Inc | 54 | |
| Christopher MD | MacroGenics | N/A | |
| Steven Chan | Connect Biopharma Holdings | 52 | |
| Peter Hurt | InflaRx NV | N/A | |
| Kafi Boaten | InflaRx NV | N/A | |
| Raul Collazo | Connect Biopharma Holdings | 58 | |
| Evelyn RothGeissler | InflaRx NV | N/A | |
| Robert MD | Clene Inc | 67 | |
| Bruce Burnett | InflaRx NV | N/A | |
| Erin JD | Shattuck Labs | 44 | |
| Elizabeth CPA | Context Therapeutics | N/A | |
| Evan Dick | Context Therapeutics | 72 | |
| MD MBA | Shattuck Labs | 67 | |
| Lei Sun | Connect Biopharma Holdings | 62 | |
| David CPA | Oramed Pharmaceuticals | 40 | |
| Andrew MBA | Shattuck Labs | 40 | |
| Tae Mgt | Clene Inc | 53 | |
| Jennifer MinaiAzary | Context Therapeutics | 48 | |
Management Performance
| Return On Equity | -0.6 | ||||
| Return On Asset | -0.29 |
Ovid Therapeutics Leadership Team
Elected by the shareholders, the Ovid Therapeutics' board of directors comprises two types of representatives: Ovid Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Ovid. The board's role is to monitor Ovid Therapeutics' management team and ensure that shareholders' interests are well served. Ovid Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Ovid Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Meg Alexander, Chief Officer | ||
| Claude MD, Head RD | ||
| SPHR SHRMSCP, VP Facilities | ||
| Victoria Fort, Senior Strategy | ||
| Jason MBA, Chief Officer | ||
| Lora Pike, Senior Relations | ||
| Garret Bonney, Investor Officer | ||
| Margaret Alexander, President COO | ||
| Dirk Haasner, Senior Vice President - Global Regulatory Affairs | ||
| MBA JD, General Counsel | ||
| Simon Kelner, Chief Officer | ||
| MBA MD, Chief Officer | ||
| Zoology Dphil, CEO Pres | ||
| Julia Tsai, Senior Development | ||
| Charles Carter, Senior Planning | ||
| MS MD, Chief Officer | ||
| Tom Parry, Vice Development | ||
| Toshiya DVM, Head Research | ||
| Zhong Zhong, Chief Officer | ||
| Manoj MD, Chief Officer | ||
| DSc FACP, Founder Board | ||
| Jeffrey Rona, Principal Officer | ||
| Amanda MD, Chief Officer | ||
| MPH MD, Senior Affairs |
Ovid Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Ovid Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.6 | ||||
| Return On Asset | -0.29 | ||||
| Operating Margin | (94.87) % | ||||
| Current Valuation | 89.64 M | ||||
| Shares Outstanding | 71.21 M | ||||
| Shares Owned By Insiders | 9.81 % | ||||
| Shares Owned By Institutions | 38.90 % | ||||
| Number Of Shares Shorted | 4.84 M | ||||
| Price To Earning | 1.11 X | ||||
| Price To Book | 2.27 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Ovid Therapeutics is a strong investment it is important to analyze Ovid Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ovid Therapeutics' future performance. For an informed investment choice regarding Ovid Stock, refer to the following important reports:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Ovid Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. For information on how to trade Ovid Stock refer to our How to Trade Ovid Stock guide.You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Will Biotechnology sector continue expanding? Could Ovid diversify its offerings? Factors like these will boost the valuation of Ovid Therapeutics. Anticipated expansion of Ovid directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Ovid Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (0.50) | Revenue Per Share | Quarterly Revenue Growth (0.24) | Return On Assets | Return On Equity |
Ovid Therapeutics's market price often diverges from its book value, the accounting figure shown on Ovid's balance sheet. Smart investors calculate Ovid Therapeutics' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since Ovid Therapeutics' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between Ovid Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Ovid Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Ovid Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.